Following a couple of strategic developments, DiaMedica Therapeutics Inc.'s (NASDAQ: DMAC) shares are surging on US stock charts today. As of the most recent check, DMAC stock has gained 30.97% during the current-market session, reaching $2.96.
- Agreement Details
- Expanding Clinical Trial To Preeclampsia
Agreement Details
DiaMedica (DMAC) has signed definitive agreements to offer its common shares to accredited investors in a private placement. DMAC expects to receive $11.8 million in gross proceeds from this transaction. As per the conditions mentioned in the securities purchase agreements, DiaMedica will issue 4,720,000 common shares at a $2.50 per share purchase price.
The anticipated closing date of this private placement is June 28, 2024, subject to the satisfaction of normal closing requirements. The net proceeds of this private placement will be used to further DiaMedica's efforts related to product development and clinical research, particularly with regard to DM199.
This involves increasing clinical research on preeclampsia and sponsoring the crucial Phase 2/3 ReMEDy2 study for the treatment of acute ischemic stroke. The money will also go toward general business objectives and additional working capital, extending DiaMedica's financial runway until the third quarter of 2026.
Expanding Clinical Trial To Preeclampsia
Additionally, DiaMedica has disclosed that it intends to broaden clinical studies into preeclampsia, a hypertensive pregnancy disease for which there are no FDA-approved therapies and huge unmet medical needs. Preeclampsia is a potentially fatal illness that is marked by newly developed hypertension, proteinuria, and/or end organ malfunction. It poses serious dangers to both the mother and the unborn child.
As of right now, neither Europe nor the United States have authorized therapies for preeclampsia. Studies show that DM199 can successfully reduce blood pressure. DM199 is a big molecule protein that has been demonstrated in animal experiments to not penetrate the placental barrier, potentially providing a considerable safety advantage in illnesses associated to pregnancy, unlike small molecule anti-hypertensives, which are contraindicated.
With up to 120 participants and an expected cost of around $1.5 million, the preeclampsia study is planned to be very cost-efficient and provide a solid proof of concept for this indication.
在一些战略性发展过后,Diamedica Therapeutics Inc. (纳斯达克股票代码:DMAC)的股票今天在美国股票交易图表上大涨。截至最近一次检查,DMAC股票在当天市场交易中上涨了30.97%,达到2.96美元。
协议详情
DiaMedica(DMAC)已经签署了关于向认可投资者提供普通股的最终协议。根据证券购买协议中的条件,DiaMedica将以每股2.5美元的价格发行4,720,000股普通股,DMAC预计将从此交易中获得1180万美元的总收益。
此次定向增发的预计截止日期为2024年6月28日,取决于正常的交割要求得到满足。此次私募股权的净收益将用于进一步推动DiaMedica的产品开发和临床研究,特别是与DM199有关的临床研究。
这涉及到扩大早产子痫症的临床研究,并赞助针对急性缺血性脑卒中治疗的重要2/3阶段ReMEDy2研究。这些资金还将用于一般业务目标和额外的运营资本,从而延长DiaMedica的财务行业,直至2026年第三季度。
扩大针对早产子痫症的临床试验
另外,DiaMedica还公开表示拟将临床研究扩大到子痫症,这是一种没有FDA批准的治疗方法和巨大的医疗需求的高血压妊娠疾病。子痫症是一种可能致命的疾病,新近发生的高血压,蛋白尿,和(或)内部器官的功能障碍是此病的特点。它对母亲和未出生的婴儿都带来严重的危险。
截至目前,欧洲和美国都没有为子痫症授权的疗法。研究表明,DM199可以成功降低血压。DM199是一种大分子蛋白质,动物实验已经证明它不能穿过胎盘屏障,与小分子抗高血压药相比,这可能提供了相当大的安全优势。
早产子痫症的研究计划招募最多120名参与者,预计成本约为150万美元,这样是非常高效的成本,并为此指示提供了有力的概念证明。